Leeford scales science-led skincare bet with Alite as acne-care demand surges

Drugmaker taps 1 million retail touchpoints, quick commerce and modern trade to expand ingredient-led skincare franchise

Redcliffe Labs sells Crysta IVF to MMG Group’s Moon Care to sharpen diagnostics play

Divestment marks Redcliffe’s strategic pivot toward preventive and advanced diagnostics; Crysta IVF to continue under existing leadership

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners

KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Zydus gets USFDA final approval for generic Dapagliflozin with 180-day shared exclusivity

Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility

Merck expands Bengaluru plant to strengthen global filtration supply chain

New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network

Symeres and Ambagon team up to target ‘undruggable’ proteins in colorectal cancer

Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies